Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust, Lisburn Road, Belfast, UK; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Jubilee Road, Belfast, UK.
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Jubilee Road, Belfast, UK.
Radiother Oncol. 2024 Jan;190:110004. doi: 10.1016/j.radonc.2023.110004. Epub 2023 Nov 14.
Despite technological advances in radiotherapy (RT), cardiotoxicity remains a common complication in patients with lung, oesophageal and breast cancers. Statin therapy has been shown to have pleiotropic properties beyond its lipid-lowering effects. Previous murine models have shown statin therapy can reduce short-term functional effects of whole-heart irradiation. In this study, we assessed the efficacy of atorvastatin in protecting against the late effects of radiation exposure on systolic function, cardiac conduction, and atrial natriuretic peptide (ANP) following a clinically relevant partial-heart radiation exposure.
Female, 12-week old, C57BL/6j mice received an image-guided 16 Gy X-ray field to the base of the heart using a small animal radiotherapy research platform (SARRP), with or without atorvastatin from 1 week prior to irradiation until the end of the experiment. The animals were followed for 50 weeks with longitudinal transthoracic echocardiography (TTE) and electrocardiography (ECG) every 10 weeks, and plasma ANP every 20 weeks.
At 30-50 weeks, mild left ventricular systolic function impairment observed in the RT control group was less apparent in animals receiving atorvastatin. ECG analysis demonstrated prolongation of components of cardiac conduction related to the heart base at 10 and 30 weeks in the RT control group but not in animals treated with atorvastatin. In contrast to systolic function, conduction disturbances resolved at later time-points with radiation alone. ANP reductions were lower in irradiated animals receiving atorvastatin at 30 and 50 weeks.
Atorvastatin prevents left ventricular systolic dysfunction, and the perturbation of cardiac conduction following partial heart irradiation. If confirmed in clinical studies, these data would support the use of statin therapy for cardioprotection during thoracic radiotherapy.
尽管放疗(RT)技术取得了进步,但心脏毒性仍然是肺癌、食道癌和乳腺癌患者的常见并发症。他汀类药物治疗除了降低血脂作用外,还具有多种作用。以前的鼠模型研究表明,他汀类药物治疗可以减轻全心脏照射的短期功能影响。在这项研究中,我们评估了阿托伐他汀在保护部分心脏照射后心脏收缩功能、心脏传导和心房利钠肽(ANP)的晚期辐射效应方面的疗效。
雌性,12 周龄,C57BL/6j 小鼠使用小动物放疗研究平台(SARRP)接受图像引导的 16Gy X 射线照射心脏底部,照射前 1 周开始用阿托伐他汀治疗,直至实验结束。动物随访 50 周,每 10 周进行一次经胸超声心动图(TTE)和心电图(ECG)检查,每 20 周检查一次血浆 ANP。
在 30-50 周时,RT 对照组观察到的轻度左心室收缩功能障碍在接受阿托伐他汀治疗的动物中不太明显。心电图分析表明,在 RT 对照组的心脏基部的心脏传导成分在 10 和 30 周时延长,但在接受阿托伐他汀治疗的动物中没有。与收缩功能不同,仅辐射会导致传导障碍在后期时间点得到解决。在接受阿托伐他汀治疗的照射动物中,30 和 50 周时 ANP 降低幅度较低。
阿托伐他汀可预防部分心脏照射后左心室收缩功能障碍和心脏传导紊乱。如果在临床研究中得到证实,这些数据将支持在胸部放疗期间使用他汀类药物进行心脏保护。